Highlights from the December CHMP meeting 2017

From their meeting in December, the European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP) has published the highlights.

At this meeting there were seven recommendations for approvals of medicines, including two orphan medicines, one of which is also an advanced therapy medicinal product (ATMP) named Alofisel (darvadstrocel). One biosimilar medicine named Herzuma (trastuzumab), was recommended for approval and two generic medicines received a positive opinion from the CHMP.

For the meeting summary, and a full list of approvals, opinions and withdrawals, please click here.